Therefore, the use of long-lasting PP analogs or inhibition of PP degradation has emerged as an effective strategy to treat obesity in recent years (3, 20, 21), which may be clinically relevant. This evidence concerns the gene PPY and obesity due to melanocortin 4 receptor deficiency.